Citizens Jmp Issues Pessimistic Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price

Posted by Brenda Bartman on Aug 6th, 2026

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) had its target price lowered by stock analysts at Citizens Jmp from $146.00 to $137.00 in a report issued on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s target price would suggest a potential upside of 29.50% from the company’s previous close.

A number of other brokerages have also recently issued reports on MIRM. Stifel Nicolaus set a $136.00 target price on Mirum Pharmaceuticals in a research report on Thursday, May 7th. JPMorgan Chase & Co. lifted their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, July 2nd. Weiss Ratings cut shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd. Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Thursday. Finally, Evercore reissued an “outperform” rating and set a $138.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $139.80.

Check Out Our Latest Stock Report on MIRM

Mirum Pharmaceuticals Stock Up 1.4%

Mirum Pharmaceuticals stock opened at $105.79 on Thursday. The firm has a market capitalization of $6.45 billion, a P/E ratio of -7.77 and a beta of 0.52. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals has a twelve month low of $50.25 and a twelve month high of $130.00. The stock’s fifty day simple moving average is $110.46 and its 200-day simple moving average is $101.77.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The firm had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. During the same period last year, the business earned ($0.12) EPS. The firm’s revenue was up 37.9% compared to the same quarter last year. As a group, equities analysts expect that Mirum Pharmaceuticals will post -2.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,721 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00. Following the completion of the sale, the senior vice president directly owned 3,114 shares in the company, valued at $373,680. This represents a 46.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares in the company, valued at $18,622,574.56. The trade was a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,155 shares of company stock valued at $7,185,662 in the last quarter. 8.32% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB grew its stake in shares of Mirum Pharmaceuticals by 1.6% during the second quarter. Handelsbanken Fonder AB now owns 197,179 shares of the company’s stock valued at $23,084,000 after acquiring an additional 3,179 shares in the last quarter. Contravisory Investment Management Inc. boosted its holdings in Mirum Pharmaceuticals by 2.3% in the second quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock valued at $539,000 after purchasing an additional 103 shares during the last quarter. Glenmede Trust Co. NA grew its stake in Mirum Pharmaceuticals by 66.9% during the 1st quarter. Glenmede Trust Co. NA now owns 5,532 shares of the company’s stock valued at $511,000 after purchasing an additional 2,217 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Mirum Pharmaceuticals by 14.5% during the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after purchasing an additional 880,505 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Mirum Pharmaceuticals in the 1st quarter valued at approximately $573,000.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

Positive Sentiment: Mirum reported second-quarter revenue of $176.24 million, up 37.9% year over year and above the $166.33 million consensus estimate. The company also raised or reaffirmed full-year 2026 revenue guidance at $680 million-$700 million, ahead of Wall Street’s $675.1 million estimate. Mirum Pharmaceuticals Q2 earnings report
Positive Sentiment: Analyst sentiment remains broadly favorable, with a consensus “Moderate Buy” rating and an average price target of $143.40, well above the recent trading level. Morgan Stanley previously raised its target to $150 and maintained an overweight rating. Mirum Pharmaceuticals analyst ratings
Neutral Sentiment: The Q2 earnings call transcript provides additional management commentary for investors, but the supplied reports do not identify a specific new catalyst or change in the company’s development and commercialization outlook. Mirum Pharmaceuticals Q2 2026 earnings call transcript
Negative Sentiment: Mirum posted a quarterly loss of approximately $0.80 per share on an adjusted basis, narrowly missing the $0.77 consensus estimate; the reported $1.06 per-share loss under another earnings measure was also below expectations. The loss widened from $0.12 per share a year earlier, highlighting continued profitability pressure. Mirum Pharmaceuticals Q2 loss report
Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth $193,733.60, reducing her direct holdings by 59.09%. Because the transaction was made under a pre-arranged Rule 10b5-1 plan, it may be less concerning than discretionary selling, but it nevertheless adds modest selling pressure. Mirum Pharmaceuticals insider sale

Mirum Pharmaceuticals Company Profile

(Get Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.